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Abstract
Background: Balance problems are caused by multiple factors and often lead to falls and related fractures, bringing
large socio-economic costs. The complexity of balance control mechanisms, the lack of medical expertise, and the
absence of specialised equipment contribute to the delayed or incorrect diagnosis and management ofthese
patients. Advances in computer science have allowed the development of computer systems that support clinical
diagnosis and treatment decisions based on individualised patient data. The aim of the EMBalance decision support
system (DSS) is to support doctors facing this clinical challenge, to make a definitive diagnosis and implement an
effective management plan. The EMBalance study will determine the accuracy of this supportive tool when used by
non-specialist doctors. This study is funded by the European Union’s Seventh Framework Programme.
Methods/design: EMBalance is a proof-of-concept study designed as a non-commercial, international, multi-centre,
single-blind, parallel-group randomised controlled trial to be carried out at four clinical sites in the United Kingdom,
Germany, Greece and Belgium. The study is comprised of three stages: internal pilot, phase I (diagnosis) and stage II
(management). For this purpose, 200 patients presenting with persistent dizziness (>3 months’ duration) to primary
care services will be randomised to either the intervention group (diagnostic assessment with the DSS) or a control
group (diagnostic assessment without the DSS). Patients allocated to the intervention group will be assessed by a
doctor with the support of the EMBalance DSS, while patients allocated to the control group will receive a visit as
per standard practice. Ultimately, all patients’ diagnoses and management plans will be certified by a consultant in
neuro-otology.
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Discussion: EMBalance is the first trial to test the accuracy of a DSS in both the diagnosis of and the management
plan for vestibular disorders across the healthcare systems of four different countries. The EMBalance study is the
result of a combined effort of engineers and physicians to develop an accurate tool to support non-specialist
doctors, with no risk for the patient. This trial will provide reliable information about the benefits of implementing
DSSs in primary care while supporting the feasibility of testing the EMBalance algorithms in further research.
Trial registration: ClinicalTrials.gov NCT02704819. Registered 29 February 2016.
Keywords: Vestibular disease, Dizziness, Vertigo, Decision support system, Randomised controlled trial, Feasibility
study
Abbreviations: AVM, Audiovestibular medicine; CI, Chief investigator; CRF, Case report form; DSS, Decision support
system; Dx, Diagnosis; ENT, Ear, nose and throat; EU, European Union; GUI, Graphical user interface;
Mng, Management; REC, Research ethics committee; RCT, Randomised controlled trial; SPIRIT, Standard Protocol
Items: Recommendations for Interventional Trials; UCL, University College London; JRMO, Joint Research
Management Office
Background
Human balance is crucial for an individual’s mobility and
independence. Balance depends on integration of vestibular,
vision and proprioceptive sensory input within the central
nervous system and generation of appropriate motor and
other responses that support stance, locomotion and orien-
tation [1]. Dizziness and imbalance symptoms are amongst
the most common reasons for visits to a doctor and affect
up to 30–40 % of the population by 60 years of age [2, 3].
Healthcare service provision to address vestibular disor-
ders remains inadequate and is regarded as a low prior-
ity [4]. Non-specialist physicians may feel overwhelmed
when faced with a patient complaining of ‘dizziness’,
owing to the vagueness of this symptom and the pleth-
ora of underlying pathologies. Narrowing the symptom
to the causative system (e.g., cardiovascular, neurological,
otological) or as being iatrogenic (e.g., a drug-related ad-
verse reaction) is a challenging process. Unsurprisingly, in
both the United States and the United Kingdom, patients
require an average of 4.5 visits with their healthcare pro-
viders before receiving a correct diagnosis and appropriate
treatment plan [4].
The complexity of balance control mechanisms, the lack
of medical expertise, and the absence of specialised equip-
ment can be contributory factors to this late diagnosis and
the resulting mismanagement of patients with balance
disorders [5, 6]. This has a considerable socio-economic
impact on the affected individual and the individual’s
family and exerts a high burden on society and the
health services [7]. Misdiagnosis and mismanagement
lead to increased personal burden on the patient and a
wide-scale burden on health economics and society [8].
Advances in computer science and artificial intelligence
have allowed the development of computer systems that
support clinical diagnosis or therapeutic and treatment
decisions based on individualised patient data [9, 10]. De-
cision support systems (DSSs) in particular are aimed at
codifying and strategically managing biomedical know-
ledge to handle clinical challenges using mathematical
modelling tools, medical data-processing techniques, and
artificial intelligence methods [11–13]. However, a review
of existing DSSs used in medicine demonstrated that there
are but few successful integrated software systems or
stand-alone tools which address the early diagnosis and
effective management of balance disorders [14]. Current
DSSs mainly target diagnosis, but none provide manage-
ment and/or rehabilitation support. There is also limited
information in the time domain (follow-up visits) and
very limited literature on detailed balance-related models,
while there are no vestibular models currently integrated
into a DSS or used in clinical practice, and no patient-
specific models [14].
EMBalance is a European project funded by the
European Union’s Seventh Framework Programme for
Research. Its aim is to develop a DSS to support clinical
decision-making, facilitate accurate diagnosis and advise
on efficient treatment of balance disorders. The final out-
come of the EMBalance project will be an Internet-based
platform provided to primary and secondary care physi-
cians across specialties, all levels of training, and with
no geographical boundaries, with the objectives of early
diagnostic evaluation and effective management of bal-
ance disorders.
The EMBalance decision support system
The EMBalance DSS is a multilanguage platform that
consists of three modules: the database, the back end
and the graphical user interface (GUI):
 The database of the system is the implementation
of the repository. The repository has been modelled
using entity relationship modelling notation and
MySQL Workbench, an open source software
programme that has been developed by Oracle
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(Redwood Shores, CA, USA) and supports a
relational database-modelling and development
approach. MySQL Workbench was also used for
the administration of the repository. In total, the
EMBalance repository is composed of 48 entities,
including instance tables (actual clinical data
collected from 1100 patients’ records), and type
tables, which are the values used to populate an
attribute of the instance tables (e.g., patient
occupation). Of these, 16 tables store many-to-many
relationships.
 The back end is used to implement the
functionalities of the system and is composed of the
configuration, the entities, the services and the
repository.
 The GUI, also known as front end, is a user-friendly
and easy-to-understand Internet-based tool that the
clinician uses to input patient information, which
subsequently feeds into the repository to generate
assisted diagnosis and management outcomes.
The interface has been developed using the Spring
Framework for the back end of the tool and the
Ext JS Framework for the GUI.
The primary users of the platform are non-specialist
doctors (e.g., general practitioners), and its intended use
has the following characteristics:
 The doctors can pace the process any way they
see fit (e.g., by switching from history-taking to
examination, stopping at any point or going back to
medical history) or by stopping the process entirely.
 The doctors who use the DSS will be asked to
exercise their clinical judgement in order to come
up with a diagnosis or management plan.
 Although the EMBalance DSS platform will propose
two or three diagnoses (with probability estimation
for each), the doctors will be asked to either choose
one of these or discard them and choose their own.
 At the end of this process, a specialist consultant
will evaluate the patient to provide the definitive
patient diagnosis and management plan; hence,
patient care will not be affected other than by a
longer-winded process for the patient.
Methods/design
EMBalance is a feasibility and/or proof-of-concept study.
It is designed as a non-commercial, international, multi-
centre, single-blind, parallel-group randomised controlled
trial (RCT) in accordance with the Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT)
guidelines [15] (see Additional file 1). The EMBalance
study will be carried out simultaneously in the United
Kingdom, Germany, Greece and Belgium. Both primary
and tertiary care settings will be involved in these four
countries. Table 1 provides the names of all participat-
ing clinical centres.
Study participants and subject selection
The primary participants in this study are the non-
specialist doctors as users of the DSS. This is to provide
a proof of concept of the DSS in aiding diagnosis and
management of the ‘dizzy’ patient. Participating doctors
are divided into two groups: non-specialist doctors and
overseeing experts.
Non-specialist doctors
The non-specialist doctors are defined as those who do
not necessarily focus their clinical interest in balance
disorders and who manage a range of patient categories.
These doctors are the first point of access for patients
seeking medical advice. All participating non-specialist
doctors will be registered with their local medical boards,
will have completed all required basic medical or other
allied health education, and will have some clinical experi-
ence in managing patients in general. All non-specialist
doctors will receive a 1-h training session during the site
induction clinic on how to use the EMBalance DSS plat-
form. The group of non-specialist doctors in each country
will be composed of the following:
 UK: general practitioners
Table 1 Participating centres: a comprehensive list of primary and tertiary care settings in the EMBalance study across Europe
Institution Primary care setting Tertiary care setting
Greece (University of Athens) Hippocrateio Hospital Hippocrateio Hospital
Belgium (Antwerp University) Antwerp University Hospital Antwerp University Hospital
Germany (University of Freiburg) Freiburg University Medical Centre Freiburg University Medical Centre
UK (University College London) Keats Group Practice National Hospital for Neurology and Neurosurgery
Hampstead Group Practice
Parliament Hill Practice
James Wigg Practice
Brondesbury Medical Centre
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 Belgium and Greece: ear, nose and throat (ENT)
residents
 Germany: neurology residents
Overseeing experts
The overseeing experts will be members of the EMBalance
consortium, who are highly experienced in the manage-
ment of vestibular disorders. They will verify the appro-
priate diagnosis and management of each patient whilst
being blinded to the previous use of the DSS by the
non-specialist doctor. They will represent the gold stand-
ard for vestibular diagnosis and management. The expertise
of the consortium is well documented, based on academic
profile, years of experience, number of publications in
relevant journals and conferences as well as relevant
chapters in textbooks, and leading roles in educational
and professional associations. The group of overseeing
experts in each country is composed of the following:
 United Kingdom: consultants in audiovestibular
medicine (AVM)
 Belgium and Greece: ENT specialists with >10 years’
expertise in AVM/neuro-otology
 Germany: neurologists
Patients will be recruited into the study on the basis of
the inclusion and exclusion criteria listed in Table 2.
Patients who present with balance-related symptoms
(specifically, vertigo or dizziness exacerbated by head
movements) in primary care will be randomised into
one of two groups:
 Intervention group (non-specialist doctor + DSS):
Patients will be seen by a non-specialist doctor with
the support of the DSS.
 Control group (non-specialist doctor −DSS): Patients
will receive a standard visit with the non-specialist
doctor without use of the DSS.
Ultimately, all patients’ cases will be reviewed by an over-
seeing expert, who will validate the clinical information
collected. The overseeing expert will rate the diagnosis and
management decisions made by the non-specialist doctor
(both with and without the DSS) as correct or incorrect
to assess whether the use of the EMBalance DSS leads
to the correct diagnosis and improved management. In
the event of disagreement, the overseeing expert will
provide the final diagnosis and management plan for
the patient according to evidence-based guidelines.
Schedule of intervention
The EMBalance feasibility study is comprised of two
parts: part I, in which patients are reviewed by the non-
specialist doctors with or without the DSS to come to a
diagnosis and devise a care plan, which is then reviewed
by the overseeing expert; and part II, which refers to the
management arm of the study and follow-up of all pa-
tients included. Part II will be carried out in the United
Kingdom and Greece exclusively. A study diagram sum-
marising the recruitment and intervention procedures is
provided in Additional file 2.
Internal pilot
Owing to the limited time frame, this project includes
an internal pilot phase. The first two non-specialist doc-
tors and four to six patients entering the trial will provide
a realistic overview of the potential barriers in connection
with this protocol and study design. This is expected to
happen during the first month of the trial. The pilot phase
will follow the same study procedures described for
parts I and II.
Part I: diagnosis and management plan assessment
On the day of recruitment, patients will initially be ex-
amined by the non-specialist doctor, either with or with-
out the DSS, according to randomisation result. In both
the + DSS and −DSS groups, each patient will undergo
the investigations required, following which the non-
specialist doctor will formulate an initial diagnosis and
management plan. The patient will then be invited to
attend a specialist neuro-otology clinic, where they will
be seen by an overseeing expert to undergo a gold stand-
ard diagnostic process and to determine the manage-
ment plan appropriate to the diagnosis, which will be
compared with the management plan previously advised
by the non-specialist doctor. The overseeing expert will
review investigations carried out and results assessed by
the non-specialist doctor. In the event that the doctor’s
assessment differs from the conclusion of the expert, the
latter will decide on the final diagnosis and management
plan of the patient according to current evidence-based
guidelines.
Table 2 Inclusion and exclusion criteria
Inclusion criteria
• Aged 18–90 years
• Capable of understanding the information provided
• Absence of dementia and/or uncontrolled psychiatric disorder
• Vertigo or chronic dizziness exacerbated by head movements
(<12 months)
• Sub-acute presentation of dizziness (0–3 months) without presenting
to emergency services
Exclusion criteria
• Aged <18 or >90 years
• Learning disabilities or dementia
• Uncontrolled psychiatric disorders
• Pregnant and breastfeeding women
• Incapable of or unwilling to give informed consent
• Acute vestibular disorders (<3 months) presented at accident and
emergency services
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Part II: delivery of the vestibular rehabilitation programme
Those patients who require vestibular physiotherapy will
enter the second part of the study. Alternatively, for pa-
tients not eligible for vestibular physiotherapy, the DSS
will propose an alternative management plan, such as
pharmacological treatment or a dietary intervention. In-
dependently of the management plan applied, all pa-
tients will be reviewed after 3-month follow-up by the
overseeing expert.
Once the diagnosis and treatment plan are agreed, pa-
tients requiring the vestibular rehabilitation programme
will receive a 3-month treatment as explained below:
 +DSS group: Patients will be seen by a non-specialist
physiotherapist on a monthly basis over a 3-month
period. This treatment will consist of customised
vestibular exercises. Such exercises are based on
the eye, head and postural exercises that provoke a
patient’s symptoms. Exercises incorporating gaze
fixation, head movements and postural exercises are
prescribed to promote adaptation of vestibulo-ocular
reflex and vestibulospinal reflex function. The
patient will practice up to five exercises at home
for approximately 1–2 minutes each, twice daily,
initially at a slow speed and gradually increasing
as symptoms improve. Patients presenting with
vestibular migraine will perform a maximum of
three exercises. These exercises will be chosen by
the DSS from among a range of established
exercises.
 −DSS group: Participants will receive routine
vestibular physiotherapy as per standard current
practice. The standard rehabilitation programme
might include lifestyle advice and education,
sometimes accompanied by a leaflet.
Follow-up
All participants will be reviewed after 3 months from
their inclusion in the trial for a follow-up appointment
with the specialist doctor.
Criteria for discontinuation and end-of-study definition
Participants can withdraw from the trial at any time or
if, in the opinion of the investigator or clinical team, it
is medically necessary to do so. Reasons for withdrawal
will be documented; participants who withdraw will be
returned to routine care, and no further data will be
collected. In the case of adverse events, these will be re-
corded in the medical records, and an adverse event
form will be completed and emailed to the sponsor
within the next 5 working days. When the last enrolled
participant has completed the follow-up, the research
ethics committee (REC) will be notified of the trial
completion. The final study report will be completed
within 12 months after trial completion.
Trial objectives
Primary objectives
The primary objectives of this study are (1) to determine
whether the EMBalance DSS is an accurate supportive
tool for the diagnosis and management plan of dizziness
and/or balance disorders when used by non-specialist
doctors and (2) to establish the feasibility of testing the
DSS in a large-scale RCT. These objectives will be mea-
sured as follows:
 Percentage of agreement between the diagnosis and
management plan established by the non-specialist
doctors (using the DSS and not using the DSS) and
the gold standard as determined by an overseeing
expert and according to current evidence-based
guidelines for the diagnosis and/or management of
these disorders
The primary outcome assessment criteria are shown
in Table 3.
Secondary objectives
The following secondary objectives are also being evalu-
ated in the trial:
 Assessment of the usability of DSS in primary care
 Determination of the number of referrals to secondary
care needed in both the + DSS and −DSS groups
 Determination of the number and cost of
investigations required for an accurate diagnosis by
the DSS non-specialist doctor user (+DSS) vs. the
non-DSS non-specialist doctor user (−DSS)
 Effectiveness of treatment proposed by DSS vs.
treatment proposed by non-DSS non-specialist
doctor
 Assessment of feasibility factors (participation rate,
dropout rate, reason for exclusion from the trial,
trial accomplishment with the time frame)
Sample size
Sample size was not formally calculated, owing to lack of
available data with respect to standard deviation. However,
200 participants should provide sufficient power for the
analysis. Participants will be equally distributed in the 4
countries; that is, 50 patients will be recruited in each
country. Regarding physicians, each country site will
collaborate with 2 overseeing experts and 10–15 non-
specialist doctors. The number of patients recruited per
centre will be determined by the number of non-specialist
doctors available at each site. This is because non-specialist
doctors are expected to learn from the EMBalance DSS,
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as the system will guide the doctors through the diag-
nostic procedures with access to supportive learning
material, such as video tutorials on diagnostic manoeu-
vres. To minimise the contamination effect that this might
have on non-specialist doctors’ decisions, each clinician
will be expected to see a maximum of six patients.
Competitive enrolment programs will not be imple-
mented. This decision was adopted in accordance with re-
cent evidence which suggests that competitive enrolment
practices have not proved a significant effect in study re-
cruitment, while posing ethical dilemmas and compromis-
ing the study design [16].
Recruitment procedures
The recruitment strategy was adjusted to the characteris-
tics of each participating centre. Potential participants will
be identified when they contact the research clinic. The
staff member who serves as the point of contact will ask
the patient whether he or she experiences dizziness or
vertigo. A patient who confirms these symptoms will re-
ceive a study information leaflet to consider participation.
Sequence generation
Randomisation sequences have been created for each
centre using Research Randomizer v4.0 software [17].
Eligible patients will be randomised in a 1:1 ratio (100
participants in each group). In accordance with the ran-
dom allocation sequence, a note containing the allocation
group will be placed inside an opaque, sealed envelope
which will be given to the non-specialist doctor at the
time of recruitment.
Allocation concealment
The allocation sequence will be concealed from the re-
searcher by enrolment of participants via sequentially
numbered envelopes. Additionally, a patient identification
trial number will be assigned to each envelope, which will
permit retrospective monitoring of patient allocation. The
Table 3 Primary outcome assessment criteria
Diagnosis (Dx)
Single Concurrent
If doctorDx = expert Dx 100 % If doctorDx1 + Dx2 = expertDx1 + Dx2 100 %
If doctorDx≠ expert Dx 0 % If doctorDx1 + Dx2 ≠ expertDx1 + Dx2 0 %
If doctorDx1 = expertDx1 and doctorDx2 NA/≠ expertDx2 50 %
Management (Mng)
Single Multiple
If doctorMng = expertMng 100 % Maximum number of correct Mng
plans = 2
If doctorMng1,2 = expertMng1, 2 100 %
If doctorMng≠ expertMng 0 % If doctorMng1,2 ≠ expertMng1,2 0 %
If doctorMng1 = expertMng1 and doctorMng2 NA/≠ expertMng2 50 %
Maximum number of correct Mng
plans = 3
If doctorMng1,2,3 = expertMng1,2,3 100 %
If doctorMng1,2,3 NA/≠ expertMng1,2,3 0 %
If doctorMng1 = expertMng1 and doctorMng2,3 NA/≠ expertMng2,3 33.3 %
If doctorMng1,2 = expertMng1,2 and doctorMng3 NA/≠ expertMng3 66.6 %
Maximum number of correct Mng
plans = 4
If doctorMng1,2,3,4 = expertMng1,2,3,4 100 %
If doctorMng1,2,3,4≠ expertMng1,2,3,4 0 %
If doctorMng1 = expertMng1 and doctorMng2,3,4 NA/≠ expertMng2,3,4 25 %
If doctorMng1,2 = expertMng1,2 and doctorMng3,4 NA/≠ expertMng3,4 50 %
If doctorMng1,2,3 = expertMng1,2,3 and doctorMng4 NA/≠ expertMng4 75 %
Diagnosis 100 % = correct
50 % = half correct
0 % = incorrect
Management 100 % = fully correct
>50 % =majority correct
50 % = half correct
<50 % = partially correct
0 % = incorrect
These criteria determine the level of agreement between the non-specialist doctor and the overseeing expert
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research nurse will be instructed to strictly follow this
sequence.
Blinding
The EMBalance trial is a single-blind study. The clinical
research nurse responsible for patient recruitment and
overseeing experts will be blinded.
Data collection
Non-specialist doctors and patients will enter the data in
bespoke case report forms (CRFs) in paper format, and
the CRF data will be transferred into a purpose-built elec-
tronic database. CRFs were designed and will be completed
with reference to the Joint Unit Guide for the Design, Use
and Completion of Paper Case Report Forms. The comple-
tion of CRFs will be signed off by the chief investigator
(CI) or a delegated authorised individual. A blank hard
copy of the CRF was submitted for review by the REC
and the sponsor. A copy is also included within the trial
master file.
Statistical analysis
Data analysis will be performed using SPSS version 16.0
software (SPSS, Chicago, IL, USA) and the StatXact statis-
tical software package (Cytel, Cambridge, MA, USA). Stat-
istical significance will be set to 0.05. Descriptive statistics
will be calculated and presented. Comparisons which will
be made include the following:
 Proportion of correct diagnosis by specialists to
non-specialists and treatments with and without
DSS use according to the overseeing expert’s
diagnosis and treatment
 Comparison of the number of laboratory
investigations prescribed with and without DSS use
 Comparison of the number of investigation referrals
with and without DSS use
 Comparisons of improvement according to the
patient at baseline and after 3 months of follow-up,
based on the following tool scores: Dizziness
Handicap Inventory, EQ-5D-3 L Questionnaire,
visual analogue scale scores before and after treatment
in the DSS vs. non-DSS user groups
For categorical values (e.g., referral rate), the chi-
square test will be used for comparisons between groups.
The Bonferroni correction will be used in cases of mul-
tiple comparisons. Normality will be tested with the
Kolmogorov-Smirnov test. If normality is met, Student’s
t test will be used. If not, a non-parametric Mann-
Whitney U test will be used instead. For comparisons
before and after treatment, a paired t test will be used
regarding numeric data (e.g., questionnaire scores) after
normality testing.
Because of the close monitoring of all study participants,
the proportion of missing data is not expected to be sub-
stantial. In the unlikely event that more than 10 % of values
corresponding to primary outcome measures are missing,
recruitment will be extended to collect additional data.
Monitoring and auditing
Adherence to the protocol, procedures for reporting
adverse events, and adequate data quality will be super-
vised by the sponsor. In addition, a trial steering commit-
tee composed of independent experts was established for
examining legal, ethical and data protection as well as
privacy and security issues related to the research activities
during the whole project life cycle. The CI will inform the
sponsor should she have concerns that arise from moni-
toring activities and/or if there are problems with over-
sight and/or monitoring procedures.
Confidentiality
Patient anonymity is protected and maintained by using a
unique identification trial number. No personal data will
be collected as part of the study, although sensitive infor-
mation such as ethnicity and physical condition could be
collected. Participants will be informed about the transfer
of this information to the study office and will be asked to
consent to this. At all research sites, staff share the same
duty of care to prevent unauthorised disclosure of personal
information. All personal information obtained for the trial
will be held securely, treated as strictly confidential and
managed in accordance with the Data Protection Act, the
NHS Caldicott guardian, the Research Governance Frame-
work for Health and Social Care, and REC approval.
Archiving
During the course of the study, all records are the respon-
sibility of the CI and will be kept in secure conditions.
When the trial is complete, the CI will confirm that the
study master file will be archived for 20 years, as stipulated
in line with all relevant legal and statutory requirements.
For this purpose, the master file will be transferred to an
approved long-term repository.
Discussion
The EMBalance project combines the efforts of experts
from the fields of bioengineering and medicine to create
a tool to support non-specialist doctors in their decision-
making. The EMBalance DSS was developed to aid health-
care professionals in primary care while enabling clinicians
to undertake the final decision about the management
and treatment of the patient. The design of this protocol
has been a challenge for the authors due to the need to
conceive of a harmonised protocol suitable for all clinical
settings (e.g., composition of a non-specialist doctors
group). The present document establishes the key
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requisites to obtain a unified set of data from all partici-
pating countries while taking into account the potential
benefits derived from both doctors’ and patients’
participation.
From the patient’s perspective, the use of the EMBa-
lance platform is a minimally invasive intervention which
is accompanied by multiple advantages: (1) better and
earlier diagnosis and treatment for the balance disorder,
(2) review of the participant’s case by a renowned expert
and (3) improvement of the patient’s quality of life. Des-
pite the support of the EMBalance DSS, however, non-
specialist doctors are asked to exercise their clinical
judgement, which ultimately will be compared with an ex-
pert’s opinion. Although at first glance this could nega-
tively affect doctors’ willingness to participate in the trial,
it will benefit their participation by providing guidance for
the diagnostic procedure of the ‘dizzy’ patient, access to
supporting learning material, and a unique chance to
receive feedback from national and international experts
in neuro-otology.
The use of a computer-aided system has been shown
to create some disruption of the patient-doctor relation-
ship [9]. The design of the DSS interface, ease in enter-
ing patient data and increased appointment time given
to consultation are some preliminary measures taken to
reduce this limitation and patient discomfort. Further-
more, a special section in the users’ manual is dedicated
to informing users regarding this issue and suggesting
ways to reduce this risk. The latter includes increasing
the efficiency of entering data, keeping within the time
constraints of the consultation and maintaining eye con-
tact to promote a good patient-doctor relationship, and
further emphasis is placed on the DSS as an auxiliary tool
and not a requirement. In the same line, the EMBalance
DSS has been reviewed by the Medicines and Healthcare
products Regulatory Agency, which determined that, in its
current state, the EMBalance DSS does not meet the
definition of a medical device defined within Article 1 of
Directive 93/42/EEC. This verdict was based on the fact
that the EMBalance DSS is a supportive tool and is not
intended to be a substitute for the clinician’s decision-
making capacity.
The EMBalance trial has been designed to gather,
and will be conducted with the ultimate aim of
obtaining, further evidence on the development of a
DSS that will lead to lower socio-economic costs
and foster equality of access to high-quality services for
diagnosis and management of vestibular disorders. This
proof-of-concept study will determine the feasibility of
implementing the EMBalance platform in primary care
settings across Europe and will provide a realistic prospect
of the accuracy of this innovative tool in addressing the
early diagnosis and effective management of balance
dysfunctions.
Trial status
Recruitment started in March 2016, and it is expected to
continue until September 2016.
Additional files
Additional file 1: SPIRIT checklist. (DOC 121 kb)
Additional file 2: EMBalance study diagram synthetizing the progress
through the phases of the EMBalance study from screening to follow-up.
(PDF 151 kb)
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